Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776626 | 0.89 | SMN1; SMN2 (0.42) | HDAC1HDAC2HDAC8THRBTP53 | |
| SCHEMBL5773575 | 0.79 | ALDH1A1 (0.56) | KDM4ELMNA | |
| SCHEMBL5777386 | 0.78 | LMNA (0.47) | KDM4EMAPTCNR2MAPK14LMNA | |
| SCHEMBL5769962 | 0.78 | SMN1; SMN2 (0.41) | KDM4EHDAC1HDAC2HDAC8THRB | |
| SCHEMBL5771249 | 0.76 | RAB9A (0.51) | ATMHDAC1HDAC2MAPTLMNA | |
| SCHEMBL5776674 | 0.76 | SMN1; SMN2 (0.46) | KDM4ETP53MAPTLMNATSHR | |
| SCHEMBL5773931 | 0.75 | CYP11B1 (0.44) | KDM4EHDAC1HDAC2HDAC8MAPT | |
| SCHEMBL5773415 | 0.75 | MTNR1A (0.38) | KDM4EHDAC1HDAC2HDAC8TP53 | |
| SCHEMBL5773332 | 0.74 | CNR2 (0.51) | THRBTP53MAPTCNR1CNR2 | |
| SCHEMBL5773998 | 0.74 | FFAR1 (0.46) | KDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | KDM4E 3953/4885ATM 2107/4885HDAC1 353/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | KDM4E 3347/4885ATM 2206/4885HDAC1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.